NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
RHOPRESSA (netarsudil) by Alcon. Approved for open angle glaucoma, ocular hypertension. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOPRESSA (netarsudil) is an ophthalmic solution approved by FDA on December 18, 2017, for the treatment of glaucoma and ocular hypertension. It is administered as eye drops and represents a novel mechanism of action in the glaucoma therapeutic class. The product is currently in its peak lifecycle stage, indicating strong market establishment and clinical adoption since approval.
$0.2BPart D
7.9 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Clinical Trials (2)
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Started Jun 2025
70 enrolled
Primary Open Angle Glaucoma or Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Started Aug 2024
Worked on RHOPRESSA at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.